| Document |
Document Title |
|
WO/2022/256738A1 |
Triazenes and methods of producing diazonium species from said traizenes using ultraviolet (UV) light, which provide a fast, easy, stable, scalable, and selectively-triggerable means of modifying aromatic nucleophiles, including those on...
|
|
WO/2022/246557A1 |
There is provided adjunctive D-cycloserine (DCS) augmentation of transcranial magnetic stimulation (TMS) therapy for Major Depressive Disorder (MDD). There is also provided combination therapies and therapeutic methods that include inter...
|
|
WO/2022/251481A1 |
The invention relates, in part, to methods and compounds for radiosensitizing cells and increasing efficacy of treatments for cancers.
|
|
WO/2022/245907A1 |
This disclosure provides the single-component near-infrared light-controlled IsPadC-PCM-based optogenetic systems for prokaryotic and eukaryotic cells, consisting of an evolved photosensory core module of the Idiomarina sp. bacterial phy...
|
|
WO/2022/246204A2 |
Provided are oligomeric agents, oligomeric compounds, antisense agents, and pharmaceutical compositions for reducing the amount or activity of PTBP 1 RNA in a cell or animal, and in certain instances reducing the amount of PTBP 1 protein...
|
|
WO/2022/245900A2 |
Described are pharmaceutical compositions for treating an inflammatory condition, a neurologic condition and/or a vascular condition, the composition including i) a cannabinoid and Ii) a modulator compound that acts as one or more of an ...
|
|
WO/2022/245032A1 |
The present invention relates to a photoresponsive micelle complex for treatment of inflammatory diseases and, more specifically, to a photoresponsive micelle complex for prevention or treatment of inflammatory diseases or infectious dis...
|
|
WO/2022/246149A2 |
A system for communication with an electric vehicle charging station. The system includes an electric vehicle charging station for charging an electric vehicle, a network operations center providing wired or wireless communication to at ...
|
|
WO/2022/241295A2 |
According to some embodiments, genetically engineered cells capable of expressing a set of one or more olfactory signaling pathway genes that facilitate expression of an olfactory receptor are provided herein. The genetically engineered ...
|
|
WO/2022/241302A2 |
Disclosed are compositions and methods that may be useful in the treatment and/or prevention of hearing loss caused by genetic mutation of the STRC gene. The compositions and methods disclosed herein use Lentiviral vectors to facilitate ...
|
|
WO/2022/238603A1 |
The proposed invention relates to plasma-activated liquid media for use thereof in the treatment of diseases, whether viral and/or bacterial (including antibiotic-resistant bacteria), of the upper and lower respiratory tracts in humans a...
|
|
WO/2022/237864A1 |
It has been established that inhibition of macropinocytosis in cancer cells enhances the anti-cancer efficacy of photodynamic therapy (PDT). Methods for treating cancer in a subject in need thereof include administering to a subject with...
|
|
WO/2022/235077A1 |
The present invention relates to a novel siderophore compound, a complex in which same is conjugated to a metal nanoparticle, and a novel use of the complex.
|
|
WO/2022/233795A1 |
The present application relates to substituted dyes containing bis-boron fused heterocycles and their uses as fluorescent labels. These compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.
|
|
WO/2022/234266A1 |
A method of distributing microparticles is provided, the method comprising: providing a plurality of microparticles at an insertion site in a medium; applying ultrasound to the insertion site that generates gas bubbles by cavitation at c...
|
|
WO/2022/235791A2 |
Described herein is a combination therapy for the treatment of a cancer in a subject. In one aspect, the therapy comprises selinexor and one or more second anti-cancer agents.
|
|
WO/2022/235040A1 |
The present invention relates to a complex for bioimaging, diagnosis, and treatment of cancer cells. The complex of the present invention comprises fluorescent nanoparticles and a manganese salt conjugated to the surface of the fluoresce...
|
|
WO/2022/232586A1 |
The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Examples of the diseases inclu...
|
|
WO/2022/232614A2 |
Methods and compositions are provided for treating individuals who have an oncogene-negative cancer. In some cases, such individuals have an oncogene-negative tumor(s). In some cases, they have an oncogene-negative lung cancer. In some c...
|
|
WO/2022/223626A1 |
The present invention relates to ultrasound mediated enhancement of immunotherapeutic medicinal agents and regimens, and particularly forimmunotherapeutic treatment of cancers and autoimmune diseases. More particularly, the invention pro...
|
|
WO/2022/224202A1 |
The present disclosure includes a boron containing complex that includes a boron compound including boron-10 (10B); and a carrier compound including a right-handed coiled coil-nanotube (RHCC-NT) portion, the RHCC-NT portion having at lea...
|
|
WO/2022/221464A2 |
A method for preventing and treating micrometastasis in a patient with cancer, especially breast cancer or glioblastoma tumors, by silencing TRAF3IP2 before during or in connection with treatment as described herein.
|
|
WO/2022/221559A2 |
Described herein are compositions and methods for assessing and modulating ceramide and sphingomyelin in neurological disorders.
|
|
WO/2022/221208A1 |
Various methods, systems, and devices for treating tissue ablation are disclosed. Several embodiments disclosed herein pertain to methods of treating tumors, systems used for irradiating tissue and tumors with electromagnetic radiation, ...
|
|
WO/2022/218092A1 |
The present invention relates to the technical field of photodynamic drugs and photosensitization, and relates to a deep infrared porphycene derivative, a preparation method, an anti-tumor drug, and an application. The porphycene derivat...
|
|
WO/2022/221834A2 |
A method of treating NSCLC or lung cancer in an individual including administering to the individual an effective amount of a composition comprising nanomolar potent particles comprising acylfulvene. The treatment can be based upon the i...
|
|
WO/2022/218578A1 |
The present invention is directed to a composition comprising hyaluronic acid (HA) having molecular weight Mw comprised between 500 kDa and 6,000 kDa and an HA oligomer having molecular weight Mw lower than 2,000 Da, wherein the weight r...
|
|
WO/2022/217037A1 |
Methods for treating, reducing, ameliorating or inhibiting symptoms idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia, comprising administering to a subject in need of an effective amount of a) multiple EGF-like-domains-9 (ME...
|
|
WO/2022/217035A1 |
Methods, agents, and pharmaceutical compositions are provided for treating neurodegenerative disease, for enhancing stroke recovery, and or for inhibiting ferroptosis in a subject. These agents, including 2-deoxyglucose, can be used alon...
|
|
WO/2022/216978A1 |
Disclosed herein are phthalocyanine dyes, and conjugates thereof, useful as fluorescent reporters for bioassays, for optical imaging and as therapeutic conjugates as the photosensitizing agents in light-based therapies including photoimm...
|
|
WO/2022/207704A1 |
The present invention relates to ultrasound mediated delivery of therapeutic agents to the central nervous system (CNS). Thus, the invention provides a cluster composition and a pharmaceutical composition, for use in delivery of therapeu...
|
|
WO/2022/207822A1 |
The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.
|
|
WO/2022/207705A1 |
A composite resin particle comprising a near infrared absorber according to general formula I and a resin selected from the group consisting of (poly(amino acids), polyphosphazenes, polysaccahride derivatives, poly(esters), poly(ortho es...
|
|
WO/2022/204587A1 |
Provided herein is a method of treating a bacterial infection in a disorder characterized by scaly skin in patient in need thereof. In embodiments, the method comprises: (a) administering to an affected area of the patient's skin a pharm...
|
|
WO/2022/203000A1 |
The present invention addresses the problem of providing a fusion protein that is for use in treatment or diagnosis of cancer and that is formed between a streptavidin variant and a molecule that recognizes a cancer cell or the like. The...
|
|
WO/2022/199138A1 |
Disclosed in the present invention are a nano artificial antigen presenting cell, a preparation method therefor and the use thereof, wherein the nano artificial antigen presenting cell is formed by means of encapsulating nanoparticles wi...
|
|
WO/2022/199317A1 |
The present invention belongs to the field of biomedicine, and particularly relates to an industrial production method for a staphylococcus aureus vaccine.
|
|
WO/2022/197995A1 |
Gd-encapsulated carbonaceous dots (Gd@C-dots) hold great potential in clinical translation as T1 contrast agent for magnetic resonance imaging. Disclosed are methods of using said particles as radiosensitizing agents.
|
|
WO/2022/194392A1 |
The present application relates to an aqueous solution comprising: at least one photosensitizer, at least one enhancer increasing the photosensitizing activity of a photosensitizer, and at least a viscous agent controlling the viscosity ...
|
|
WO/2022/195004A1 |
A system and method/apparatus are provided which involves the transfer of beneficial information as well as beneficial substances through the water into living organisms which consume the water. This allows for the treatment of living or...
|
|
WO/2022/194733A2 |
The invention relates to indocyanine green compositions with improved stability, especially improved storage stability. In particular, the invention relates to compositions comprising indocyanine green and an association of stabilizing c...
|
|
WO/2022/193898A1 |
A boron carrying agent, a preparation method therefor, and a pharmaceutical formulation. The boron carrying agent contains compound 1, N-4-carboxyphenylboronic acid amide-threonine-phenylalanine-phenylalanine-tyrosine-glycine
-glycine-se...
|
|
WO/2022/194731A1 |
The invention relates to indocyanine green compositions with improved stability, especially improved storage stability. In particular, the invention relates to compositions comprising indocyanine green and at least one stabilizer chosen ...
|
|
WO/2022/196509A1 |
[Problem] To provide: a catheter which makes it possible to allow a proper amount of radical anions to reach an antibody-hydrophilic phtharocyanine conjugate that is bonded to cancer cells to thereby efficiently necrotize the cancer cell...
|
|
WO/2022/190067A1 |
Disclosed are methods comprising: administering a drug-loaded nanoparticle to a subject; and exposing a target site of the subject to an alternating electric field for a period of time, the alternating electric field having a frequency a...
|
|
WO/2022/191262A1 |
Provided is a boron drug that is for boron neutron capture therapy and that is characterized by containing a compound represented by formula (I) or (II) [in the formulae, C represents a carbon atom, L1, L2, L3, and L4 each independently ...
|
|
WO/2022/188046A1 |
A chemotherapeutic drug-/photosensitizer-loaded nanomicelle, a preparation method therefor, and an application thereof, aiming at combining functions of phototherapy and chemotherapy to prepare an indocyanine green (ICG) and doxorubicin ...
|
|
WO/2022/189627A1 |
The invention concerns an in vitro or ex vivo method for delivering a cargo into a cell, the method comprising: contacting a cell with one or more photoresponsive organic particles and a cargo, wherein the cargo is not bound to the one o...
|
|
WO/2022/183811A1 |
The invention relates to the field of medical and health services, in particular to a photocatalytic nano-enzyme with a catalase-like activity, and a preparation method therefor and the use thereof. The photocatalytic nano-enzyme is prep...
|
|
WO/2022/183065A1 |
Provided herein are specific inhibitors, compositions, methods and uses for reducing expression of MARC1 in a cell or individual. Such methods, specific inhibitors, and compositions can be useful, for example, to treat a liver disease, m...
|
